Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Hepatocellular Carcinoma · Gastrointestinal Cancer Metastatic · Neuroendocrine Tumors

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Stanford University, Palo Alto, California, United States
Contact: Study coordinator (Mikayla Easterling) · maeast@stanford.edu · 650-724-3698
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Contact: Study coordinator (Veronica Faris) · veronica.faris@pennmedicine.upenn.edu · 215-573-9765

Study leads

Michael Soulen, MD
Principal Investigator
Univ. of Pennsylvania

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Colorectal Carcinoma · Endometrial Carcinoma · Melanoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Birmingham, United States · Los Angeles, United States

A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC

Hepatocellular Carcinoma (HCC)

Abroad (travel likely)RecruitingPHASE2

Hangzhou, China

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Cancer · Breast Cancer · Non-Small Cell Lung Cancer (NSCLC)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Beijing, China

Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma

Hepatocellular Carcinoma (HCC)

Abroad (travel likely)RecruitingPHASE2

Wuhan, China